Background: The number of incretin-based therapies for the management of T2D is growing, as is the number of NPs and PAs practicing in primary care, necessitating continuing education to improve knowledge and competence with T2D treatment. Practicing Clinicians Exchange (PCE) developed an educational program on GLP-1 RAs followed by virtual patient simulations to address educational and clinical application needs.

Methods: Following a series of live education, 2 virtual patient simulations were released in October 2022. NPs and PAs received immediate feedback on management decisions.

Conclusions: Patient simulations are effective educational strategy for NPs and PAs to improve competence and application of knowledge with incretin-based therapies for the management of patients with T2D. Patients in both cases were candidates for glycemic control, weight reduction, and CV risk reduction. Glycemic control was achieved by a greater percentage of learners in Case 1 vs Case 2 which could be due to a higher percentage of GLP-1 RA prescriptions (81% vs 65%). More learners achieved weight loss and recommended non-pharmacologic strategies in Case 2. Overall, most GLP-1 RAs prescribed had CV risk reduction benefits with a greater percentage prescribed in Case 1 (87.4% vs 83%). It is important to note a limitation of these findings is more learners completed Case 1 vs Case 2.


E.Brechtelsbauer: None. J.Gustafson: None. R.L.Black: None.


Novo Nordisk (73471747)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at